Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Dare Bioscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
DARE
Nasdaq
8731
https://www.darebioscience.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Dare Bioscience Inc
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
- Apr 23rd, 2024 12:00 pm
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
- Apr 11th, 2024 12:00 pm
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 8:05 pm
Q4 2023 Dare Bioscience Inc Earnings Call
- Mar 29th, 2024 1:07 pm
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
- Mar 28th, 2024 12:00 pm
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
- Mar 21st, 2024 12:00 pm
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
- Feb 22nd, 2024 1:00 pm
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
- Jan 31st, 2024 1:00 pm
Daré Bioscience Announces Executive Team and Board of Directors Changes
- Jan 26th, 2024 9:30 pm
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
- Jan 17th, 2024 1:00 pm
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
- Jan 4th, 2024 1:00 pm
When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?
- Jan 4th, 2024 12:12 pm
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
- Dec 26th, 2023 1:00 pm
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
- Dec 20th, 2023 1:00 pm
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
- Dec 13th, 2023 1:00 pm
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
- Dec 7th, 2023 1:00 pm
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
- Dec 4th, 2023 1:00 pm
20 Countries with the Highest Teenage Pregnancy Rates
- Nov 23rd, 2023 8:38 pm
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
- Nov 20th, 2023 1:00 pm
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
- Nov 13th, 2023 1:00 pm
Scroll